Liquidia Technologies LQDA 深 沪
已收盘 02-06 16:00:00 美东时间
43.04
+1.480
+3.56%
华盛通- 最 高43.89
- 今 开42.65
- 成交量 150.40万股
- 最 低 41.785
- 昨 收 41.56
- 总市值 37.44亿
- 52周最高 46.67
- 市盈率 静 --
- 换手率 1.73%
- 52周最低 11.26
- 委 比 -91.24%
- 总股本 8699.55万
- 历史最高 46.67
- 量 比 0.91
- 振 幅 5.06%
- 历史最低 2.25
- 每 手 1
- 风险率 8.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
02-05 01:35
Liquidia To Highlight Clinical Data In Pulmonary Arterial Hypertension And PH-ILD With LIQ861 And L606 At PVRI 2026 Annual Congress
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the
01-27 21:32
Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress
Liquidia Corporation will present three posters at the PVRI 2026 Annual Congress in Dublin, showcasing clinical data for its therapies LIQ861 (YUTREPIA) and L606 in pulmonary hypertension conditions. The presentations will highlight interim data from the ASCENT study on LIQ861 in PH-ILD, 48-week data for L606 in PAH and PH-ILD, and insights into cardiac effort changes from the ASCENT trial. Researchers and company executives will present the find...
01-27 13:30
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Jefferies Maintains Buy on Liquidia, Raises Price Target to $55
Jefferies analyst Amy Li maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target from $45 to $55.
01-14 04:30
Liquidia highlights strong YUTREPIA launch and growth plans
An update from Liquidia Technologies ( ($LQDA) ) is now available. On January 9...
01-09 19:58
Liquidia Posts $148.3M In 2025 And $90.1M In Q4 YUTREPIA Sales, Sees Strong Momentum Into 2026
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced preliminary,
01-09 19:33
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update
Liquidia Corporation announced preliminary financial results for 2025, with YUTREPIA net product sales of $148.3 million for the full year. Fourth-quarter sales reached $90.1 million, and cash flow exceeded $30 million. Over 2,800 unique patient prescriptions were received since the June launch. The company plans to expand clinical studies in 2026 and grow the field sales team to increase market presence.
01-09 11:30
Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference
Liquidia Corporation's CEO, Dr. Roger Jeffs, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 5:15 p.m. PT (8:15 p.m. ET) in San Francisco. A live audio webcast will be available on Liquidia’s website, with an archive accessible for 30 days. Liquidia, a biopharmaceutical company, specializes in innovative therapies for respiratory and vascular diseases using its proprietary PRINT® Technology. The company m...
01-07 12:00
美股大行评级 | 潜在涨幅121.27%！HC Wainwright & Co.：Agios Pharmaceuticals获机构升目标价至62美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Agios Pharmaceuticals"买入"评级，目标价从48美元升至62美元；Leerink Partners：维持Agios Pharmaceuticals"跑赢大市"评级，目标价从34美元升至40美元
2025-12-29 10:27
